These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
389 related items for PubMed ID: 18636999
1. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, Jie S, Mardiati R, Mokri A, Moskalewicz J, Newcombe D, Poznyak V, Subata E, Uchtenhagen A, Utami DS, Vial R, Zhao C. Addiction; 2008 Sep; 103(9):1484-92. PubMed ID: 18636999 [Abstract] [Full Text] [Related]
2. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B, MANIF2000 cohort study group. Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390 [Abstract] [Full Text] [Related]
3. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)]. Fhima A, Henrion R, Lowenstein W, Charpak Y. Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992 [Abstract] [Full Text] [Related]
4. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641 [Abstract] [Full Text] [Related]
5. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Jenkinson RA, Clark NC, Fry CL, Dobbin M. Addiction; 2005 Feb; 100(2):197-205. PubMed ID: 15679749 [Abstract] [Full Text] [Related]
6. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B. Clin Infect Dis; 2009 Nov 01; 49(9):1433-40. PubMed ID: 19807275 [Abstract] [Full Text] [Related]
7. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A. Int J Drug Policy; 2010 May 01; 21(3):229-33. PubMed ID: 19926271 [Abstract] [Full Text] [Related]
8. One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Teesson M, Ross J, Darke S, Lynskey M, Ali R, Ritter A, Cooke R. Drug Alcohol Depend; 2006 Jun 28; 83(2):174-80. PubMed ID: 16343809 [Abstract] [Full Text] [Related]
10. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)]. Duburcq A, Charpak Y, Blin P, Madec L. Rev Epidemiol Sante Publique; 2000 Aug 28; 48(4):363-73. PubMed ID: 11011303 [Abstract] [Full Text] [Related]
15. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Addiction; 2005 Feb 28; 100(2):150-8. PubMed ID: 15679744 [Abstract] [Full Text] [Related]
16. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Spire B, Lucas GM, Carrieri MP. Int J Drug Policy; 2007 Aug 28; 18(4):262-70. PubMed ID: 17689374 [Abstract] [Full Text] [Related]